Longitudinal SARS-CoV-2 antibody study using the Easy Check COVID-19 IgM/IgG™ lateral flow assay.
Since the initial identification of the novel coronavirus SARS-CoV-2 in December of 2019, researchers have raced to understand its pathogenesis and begun devising vaccine and treatment strategies. An accurate understanding of the body's temporal immune response against SARS-CoV-2 is paramount t...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0247797 |
| _version_ | 1818364234317168640 |
|---|---|
| author | Renee L Higgins Stephen A Rawlings Jamie Case Florence Y Lee Clarence W Chan Bethany Barrick Zoe C Burger Kiang-Teck J Yeo Dena Marrinucci |
| author_facet | Renee L Higgins Stephen A Rawlings Jamie Case Florence Y Lee Clarence W Chan Bethany Barrick Zoe C Burger Kiang-Teck J Yeo Dena Marrinucci |
| author_sort | Renee L Higgins |
| collection | DOAJ |
| description | Since the initial identification of the novel coronavirus SARS-CoV-2 in December of 2019, researchers have raced to understand its pathogenesis and begun devising vaccine and treatment strategies. An accurate understanding of the body's temporal immune response against SARS-CoV-2 is paramount to successful vaccine development and disease progression monitoring. To provide insight into the antibody response against SARS-CoV-2, plasma samples from 181 PCR-confirmed COVID-19 patients collected at various timepoints post-symptom onset (PSO) were tested for the presence of anti-SARS-CoV-2 IgM and IgG antibodies via lateral flow. Additionally, 21 donors were tracked over time to elucidate patient-specific immune responses. We found sustained levels of anti-SARS-CoV-2 antibodies past 130 days PSO, with 99% positivity observed at 31-60 days PSO. By 61-90 days PSO, the percentage of IgM-/IgG+ results were nearly equal to that of IgM+/IgG+ results, demonstrating a shift in the immune response with a decrease in IgM antibody levels. Results from this study not only provide evidence that the antibody response to COVID-19 can persist for over 4 months, but also demonstrates the ability of Easy Check™ to monitor seroconversion and antibody response of patients. Easy Check was sufficiently sensitive to detect antibodies in patient samples as early as 1-4 days PSO with 86% positivity observed at 5-7 days PSO. Further studies are required to determine the longevity and efficacy of anti-SARS-CoV-2 antibodies, and whether they are protective against re-infection. |
| first_indexed | 2024-12-13T22:01:08Z |
| format | Article |
| id | doaj.art-93db9cac312a404083ac685d39bc0018 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-13T22:01:08Z |
| publishDate | 2021-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-93db9cac312a404083ac685d39bc00182022-12-21T23:30:00ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-01163e024779710.1371/journal.pone.0247797Longitudinal SARS-CoV-2 antibody study using the Easy Check COVID-19 IgM/IgG™ lateral flow assay.Renee L HigginsStephen A RawlingsJamie CaseFlorence Y LeeClarence W ChanBethany BarrickZoe C BurgerKiang-Teck J YeoDena MarrinucciSince the initial identification of the novel coronavirus SARS-CoV-2 in December of 2019, researchers have raced to understand its pathogenesis and begun devising vaccine and treatment strategies. An accurate understanding of the body's temporal immune response against SARS-CoV-2 is paramount to successful vaccine development and disease progression monitoring. To provide insight into the antibody response against SARS-CoV-2, plasma samples from 181 PCR-confirmed COVID-19 patients collected at various timepoints post-symptom onset (PSO) were tested for the presence of anti-SARS-CoV-2 IgM and IgG antibodies via lateral flow. Additionally, 21 donors were tracked over time to elucidate patient-specific immune responses. We found sustained levels of anti-SARS-CoV-2 antibodies past 130 days PSO, with 99% positivity observed at 31-60 days PSO. By 61-90 days PSO, the percentage of IgM-/IgG+ results were nearly equal to that of IgM+/IgG+ results, demonstrating a shift in the immune response with a decrease in IgM antibody levels. Results from this study not only provide evidence that the antibody response to COVID-19 can persist for over 4 months, but also demonstrates the ability of Easy Check™ to monitor seroconversion and antibody response of patients. Easy Check was sufficiently sensitive to detect antibodies in patient samples as early as 1-4 days PSO with 86% positivity observed at 5-7 days PSO. Further studies are required to determine the longevity and efficacy of anti-SARS-CoV-2 antibodies, and whether they are protective against re-infection.https://doi.org/10.1371/journal.pone.0247797 |
| spellingShingle | Renee L Higgins Stephen A Rawlings Jamie Case Florence Y Lee Clarence W Chan Bethany Barrick Zoe C Burger Kiang-Teck J Yeo Dena Marrinucci Longitudinal SARS-CoV-2 antibody study using the Easy Check COVID-19 IgM/IgG™ lateral flow assay. PLoS ONE |
| title | Longitudinal SARS-CoV-2 antibody study using the Easy Check COVID-19 IgM/IgG™ lateral flow assay. |
| title_full | Longitudinal SARS-CoV-2 antibody study using the Easy Check COVID-19 IgM/IgG™ lateral flow assay. |
| title_fullStr | Longitudinal SARS-CoV-2 antibody study using the Easy Check COVID-19 IgM/IgG™ lateral flow assay. |
| title_full_unstemmed | Longitudinal SARS-CoV-2 antibody study using the Easy Check COVID-19 IgM/IgG™ lateral flow assay. |
| title_short | Longitudinal SARS-CoV-2 antibody study using the Easy Check COVID-19 IgM/IgG™ lateral flow assay. |
| title_sort | longitudinal sars cov 2 antibody study using the easy check covid 19 igm igg™ lateral flow assay |
| url | https://doi.org/10.1371/journal.pone.0247797 |
| work_keys_str_mv | AT reneelhiggins longitudinalsarscov2antibodystudyusingtheeasycheckcovid19igmigglateralflowassay AT stephenarawlings longitudinalsarscov2antibodystudyusingtheeasycheckcovid19igmigglateralflowassay AT jamiecase longitudinalsarscov2antibodystudyusingtheeasycheckcovid19igmigglateralflowassay AT florenceylee longitudinalsarscov2antibodystudyusingtheeasycheckcovid19igmigglateralflowassay AT clarencewchan longitudinalsarscov2antibodystudyusingtheeasycheckcovid19igmigglateralflowassay AT bethanybarrick longitudinalsarscov2antibodystudyusingtheeasycheckcovid19igmigglateralflowassay AT zoecburger longitudinalsarscov2antibodystudyusingtheeasycheckcovid19igmigglateralflowassay AT kiangteckjyeo longitudinalsarscov2antibodystudyusingtheeasycheckcovid19igmigglateralflowassay AT denamarrinucci longitudinalsarscov2antibodystudyusingtheeasycheckcovid19igmigglateralflowassay |